First Manhattan CO Uni Qure N.V. Transaction History

First Manhattan CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.82 - $6.93 $1,532 - $2,203	318 New	318 $1,000
Q4 2018 Jan 30, 2019	SELL	$22.8 - $33.93 $1.18 Million - $1.76 Million	-51,900 Closed	0 $0
Q3 2018 Oct 15, 2018	SELL	$29.75 - $43.08 $538,475 - $779,748	-18,100 Reduced 25.86%	51,900 $1.89 Million
Q4 2017 Jan 22, 2018	BUY	$9.47 - $19.59 $662,900 - $1.37 Million	70,000	70,000 $1.37 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.